This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Brian Vastag

JAMA. 2001;285:1565-1566.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atlanta—A new vaccine promises to decrease the number of difficult-to-treat nosocomial infections by boosting immunity against Staphylococcus aureus, a common cause of hospital-related infections. Called StaphVax, the vaccine reduced infection rates by 57% in a high-risk population for as long as 10 months, reported Gary Horwith, MD, at a meeting last month of the Advisory Committee on Immunization Practices (ACIP). The ACIP advises the Centers for Disease Control and Prevention. Horwith is vice president for clinical research of Nabi Inc, the Boca Raton, Fla, drug firm that developed StaphVax.

The phase 3 multicenter study followed up 1800 patients requiring dialysis, who were considered at high risk of infection from repeated punctures. In the group that received the vaccine, S aureus antibody levels peaked at 10 to 14 days, plateaued until about 40 weeks, then dropped to baseline as the vaccine lost its effectiveness. At 40 weeks, . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute Septic Arthritis
Shirtliff and Mader
Clin. Microbiol. Rev. 2002;15:527-544.
ABSTRACT | FULL TEXT